Trial Profile
A phase II study with CD20-positive non-Hodgkin's lymphoma treated with shorter duration of infusion of GA101(RO5072759)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms GATS trial
- Sponsors Chugai Pharmaceutical; Nippon Shinyaku
- 01 Aug 2018 Results published in the Japanese Journal of Clinical Oncology
- 06 Dec 2016 Results assessing safety and pharmacokinetics presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 27 Oct 2016 Status changed from active, no longer recruiting to completed.